Skip to main content
. 2023 Mar 8;24(6):5208. doi: 10.3390/ijms24065208

Figure 2.

Figure 2

Schematic representation of anti-PD-1/PDL1: Binding of PD-1 to its ligand, PDL-1, results in suppression of proliferation and immune response of T cells. Antibody blockade of PD-1 or PD-L1 reverses this process, resulting in enhanced anti-tumor immune responses.